Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 88 entries
View as:

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06043427 Org: User:
Start: 04/16/24 End: 06/30/26 Due: 06/30/27

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06235697 Org: User:
Start: 04/25/24 End: 04/30/33 Due: 04/30/34

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

Phase: N/A Priority: Normal
NCT ID: NCT02343718 Org: User:
Start: 06/24/15 End: 01/16/19 Due: 01/16/20

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06686771 Org: User:
Start: 07/31/25 End: 12/31/30 Due: 12/31/31

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05180097 Org: User:
Start: 11/01/22 End: 06/30/26 Due: 06/30/27

Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00482677 Org: User:
Start: 11/14/07 End: 08/10/16 Due: 08/10/17

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01101438 Org: User:
Start: 08/13/10 End: 08/18/23 Due: 08/18/24

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01846390 Org: User:
Start: 10/01/13 End: 09/19/18 Due: 09/19/19

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00993655 Org: User:
Start: 03/03/10 End: 07/11/16 Due: 07/11/17

Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01982786 Org: User:
Start: 04/22/14 End: 10/19/18 Due: 10/19/19

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01619813 Org: User:
Start: 12/14/12 End: 05/20/16 Due: 05/20/17

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02597062 Org: User:
Start: 07/05/16 End: 02/01/22 Due: 02/01/23

Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT02511522 Org: User:
Start: 12/11/15 End: 10/02/24 Due: 10/02/25

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03259035 Org: User:
Start: 06/29/18 End: 04/25/24 Due: 04/25/25

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03057106 Org: User:
Start: 03/28/17 End: 06/30/25 Due: 06/30/26

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT04650581 Org: User:
Start: 01/27/21 End: 12/31/26 Due: 12/31/27

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01622543 Org: User:
Start: 10/26/12 End: 09/12/18 Due: 09/12/19

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Phase: N/A Priority: Normal
NCT ID: NCT06592924 Org: User:
Start: 05/28/25 End: 04/15/31 Due: 04/15/32

Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases

Phase: N/A Priority: Normal
NCT ID: NCT02512965 Org: User:
Start: 01/04/16 End: 08/16/21 Due: 08/16/22

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02630693 Org: User:
Start: 04/08/16 End: 11/29/23 Due: 11/29/24

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02788773 Org: User:
Start: 12/15/16 End: 05/01/25 Due: 05/01/26

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04663997 Org: User:
Start: 08/11/21 End: 12/31/25 Due: 12/31/26

Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01708993 Org: User:
Start: 12/10/12 End: 09/26/18 Due: 09/26/19

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Phase: N/A Priority: Normal
NCT ID: NCT02537418 Org: User:
Start: 10/16/15 End: 06/30/25 Due: 06/30/26

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Phase: N/A Priority: Normal
NCT ID: NCT02740920 Org: User:
Start: 01/10/17 End: 09/30/19 Due: 09/30/20